Thalassemia in the laboratory: pearls, pitfalls, and promises.
Gunay AliyevaChingiz AsadovTahira MammadovaSurmaya GafarovaEldar AbdulalimovPublished in: Clinical chemistry and laboratory medicine (2019)
Thalassemia is one of the most common hereditary disorders of the developing world, and it is associated with severe anemia and transfusion dependence. The global health burden of thalassemia has increased as a result of human mobility and migration in recent years. Depending on inherited mutations, thalassemia patients exhibit distorted hemoglobin (Hb) patterns and deviated red cell indices, both of which can be used to support identification by diagnostic tools. Diagnostic approaches vary depending on the target population and the aim of the testing. Current methods, which are based on Hb patterns, are used for first-line screening, whereas molecular testing is needed for conformation of the results and for prenatal and preimplantation genetic diagnosis. In the present paper, we review the diagnostic parameters, pitfalls, interfering factors, and methods; currently available best-practice guidelines; quality assurance and standardization of the procedures; and promising laboratory technologies for the future of thalassemia diagnosis.
Keyphrases
- sickle cell disease
- global health
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- pregnant women
- endothelial cells
- healthcare
- primary care
- public health
- single cell
- peritoneal dialysis
- stem cells
- acute kidney injury
- gene expression
- induced pluripotent stem cells
- risk factors
- cardiac surgery
- bone marrow
- clinical practice
- current status
- iron deficiency